Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
During the COVID-19 pandemic, a 43-year-old male patient with no clinically relevant changes, underwent routine examinations at the Brazilian Army Institute of Biology on 25 May 2021. The fourth-generation chemiluminescence assay, Vitros HIV Combo (Ortho Clinical Diagnostics, New Jersey, USA), for HIV-1 and HIV-2 was performed. The Vitros HIV Combo test detects both HIV-1 and HIV-2 antibodies and the p24 antigen in acute cases of HIV infection. The result obtained was 2.54 s/CO (sample relative light unit/cut-off relative light unit). Specimens with s/CO values of ≥1 are considered reactive for HIV. Following the flowchart established by the Technical Manual for the Diagnosis of HIV Infection in Adults and Children, prepared by the Brazilian Health Ministry,1 a new sample was obtained on 4 June 2021, for confirmation and additional quantification of HIV-1 viral load using real-time reverse transcription PCR (M2000sp and M2000rt; Laboratories, Abbott Park, Illinois, USA) and an antibody specific search for viral HIV-1 antigens (p17, p24, p31, gp41, p51, p55, p66 and gp120/160) using western blotting. The new chemiluminescent HIV-1/HIV12 test showed reactivity at 2.67 s/CO, similar to the first …
Handling editor Tahir S Pillay.
Contributors MdCC collected data and drafted the initial manuscript; MD-R critically reviewed the manuscript; CGMS critically reviewed and approved of the final submission.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.